Gilead's sofosbuvir aces Japanese hep C trial; Merck KGaA rejigs top management; J&J marketing exec jumps ship;

@FiercePharma: Top-read on FiercePharmaMarketing yesterday: Eli Lilly's sales force finds CRM harmony in the cloud. Story | Follow @FiercePharma

@TracyStaton: Still best-read FiercePharma: It's a big win for Eli Lilly in multibillion-dollar Alimta patent fight. More | Follow @TracyStaton

@EricPFierce: Hikma invested $39M in NJ plant for which FDA has now closed out a warning letter from 2012. News | Follow @EricPFierce

@CarlyHFierce: GSK will tailor vaccine portfolio, improve access as part of wider Africa initiative. Article | Follow @CarlyHFierce

> Gilead Sciences ($GILD) said a key Japanese trial of its hepatitis C drug sofosbuvir showed the drug crushed the virus in 98% of previously untreated patients. Report

> Merck KGaA shuffled top management to put its consumer health chief, Udit Batra, in charge of its Millipore division, and its allergy business CEO, Uta Kemmerick-Keil, at the helm of the consumer business. Release

> Johnson & Johnson's ($JNJ) Kim Kadlec, worldwide VP of its global marketing group, jumped ship to head up relationship management at AOL. Report

> Some Indian officials are moving ahead with a bid to issue a compulsory license on Bristol-Myers Squibb's ($BMY) cancer drug Sprycel in spite of questions about the rationale behind the move. Report

> Astellas filed for European approval for broader use of its prostate cancer drug Xtandi, in patients who haven't yet had chemo. Report

Medical Device News

@FierceMedDev: Breaking: Cardinal Health is snatching up device maker AccessClosure for $320M. Story | Follow @FierceMedDev

@MarkHFierce: Last year, my sister died, and I learned first-hand about life sciences' limits. Editor's corner | Follow @MarkHFierce

@MichaelGFierce: ICYMI: The year in nanotech drug delivery. Report | Follow @MichaelGFierce

@EmilyWFierce: The FDA approved a hand-held, portable treatment to reverse an opioid overdose. News | Follow @EmilyWFierce

> After a successful IPO, LDR looks to raise more cash. More

> Biotronik proceeds with MRI-safe ICD study in the U.S. as initial patients join in. Story

Biotech News

@FierceBiotech: Party drug turned 'miracle' cure for depression spurs hype and stubborn hope. Editor's Corner | Follow @FierceBiotech

@JohnCFierce: Celgene pays VCs $47M to up its stake in Acceleron's pipeline. More | Follow @JohnCFierce

@DamianFierce: Looking back at notes from JPM in January, Lumena said it would wait on IPO until it had more data, to drive up valuation. That was pre-Q1 boom. | Follow @DamianFierce

@EmilyMFierce: Mutations during vaccine making weakened last year's flu jab. Article via FierceVaccines | Follow @EmilyMFierce

> Lumena swings for a $75M IPO to bear down on liver diseases. Story

> Pharma giants jostle for the cancer R&D spotlight at AACR. Piece

Pharma Manufacturing News

> Apotex plant in India tagged with import ban. News

> Alexion says it will add third operation in Ireland. Story

> Merck puts big data to work to solve vaccine manufacturing concern. Article

> GSK recalls Paxil after FDA issues warning letter. News

> Hikma earns FDA closeout letter for its new Jersey plant. News

> Aurobindo gets control of 7 Actavis API plants in Europe. Brief

Vaccines News

> GlaxoSmithKline admits defeat in PhIII cancer vaccine trial. News

> Mutations during vaccine making weakened last year's flu jab. Story

> GSK will tailor vaccine portfolio, improve access as part of wider Africa initiative. Story

> CDC: Flu vaccination cuts children's risk for intensive care hospitalization. Article

> Vaccines sale figures into Baxter's breakup plans. Story

> Trump's Twitter tirade blames vaccines for autism increase. Article

And Finally... More research shows that the party drug "special K," a.k.a. ketamine, might help patients with major depressive disorder. Report

Suggested Articles

Pfizer will exit its Perth, Australia sterile injectables manufacturing site by 2024 as part of a global production reorganization effort.

Agios has withdrawn a European application for Tibsovo in AML after the same phase 1 data that earned it an FDA nod failed to impress the EMA.

Sanofi is reportedly considering a sale of some of its anti-inflammation drugs that could snare $234 million as the company pivots toward Dupixent.